Form 4: Kiniksa CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Kiniksa Pharmaceuticals International's CFO, Mark Ragosa, sold 12,000 Class A Ordinary Shares for a weighted average price of $41.89 per share under a Rule 10b5-1 plan.

Summary

• Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported a sale of company shares.
• On January 8, 2026, Mr. Ragosa disposed of 12,000 Class A Ordinary Shares.
• The shares were sold at a weighted average price of $41.89 per share.
• Individual trade prices for the transaction ranged between $41.44 and $42.24.
• This transaction was executed pursuant to a Rule 10b5-1 plan, which Mr. Ragosa established on August 14, 2025.
• Following this transaction, Mr. Ragosa beneficially owns 19,086 Class A Ordinary Shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the execution under a pre-arranged 10b5-1 plan suggests it's a planned liquidity event rather than a reaction to new, negative information, thus mitigating potential negative interpretations.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which provides transparency and indicates the sale was not based on new, non-public information, mitigating concerns about opportunistic insider selling.

Negatives

• The Chief Financial Officer reduced his direct beneficial ownership by 12,000 shares, which could be interpreted by some investors as a reduction in insider alignment, although mitigated by the 10b5-1 plan.

Risks

• While the sale was pre-scheduled under a 10b5-1 plan, a reduction in insider ownership by a key executive might be perceived as a minor risk by some investors, potentially leading to questions about management's long-term commitment or outlook.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The sale of 12,000 Class A Ordinary Shares by Chief Financial Officer Mark Ragosa is a related party transaction.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, which could lead to varied interpretations regarding management's long-term commitment, despite the transaction being pre-scheduled under a 10b5-1 plan.

Key Dates

Keywords

KNSA, Kiniksa Pharmaceuticals, Form 4, Insider Trading, Share Sale, CFO, Mark Ragosa, 10b5-1 Plan, Equity Transaction